๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for T-cell Non-Hodgkin Lymphoma

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy NCT07188558Phase 336 sites๐Ÿ“ Gilbert๐Ÿ“ Scottsdale๐Ÿ“ Scottsdale Lyell Immunopharma, Inc. ยท Tests: rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma NCT06160843Phase 21 site๐Ÿ“ Singapore National Cancer Centre, Singapore ยท Tests: Pembrolizumab IV infusion Q3W, with daily oral Olaparib. PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas NCT06530550Phase 21 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: PI3K inhibitor Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain NCT07624838n/a37 sites๐Ÿ“ A Coruรฑa๐Ÿ“ Palma de Mallorca๐Ÿ“ Palma de Mallorca Grupo Espaรฑol de Linfomas y Transplante Autรณlogo de Mรฉdula โ€ฆ ยท Tests: Brentuximab Vedotin Plus CHP A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies NCT07195916Phase 122 sites๐Ÿ“ Duarte๐Ÿ“ La Jolla๐Ÿ“ Ann Arbor Incyte Corporation ยท Tests: INCA036873 CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL NCT06559189Phase 11 site๐Ÿ“ Aurora University of Colorado, Denver ยท Tests: CD19x22 CAR T Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors NCT02508038Phase 11 site๐Ÿ“ Madison University of Wisconsin, Madison ยท Tests: TCRฮฑฮฒ+/CD19+ depleted Haploidentical HSCT, Zoledronate Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma NCT05798897Phase 17 sites๐Ÿ“ Duarte๐Ÿ“ Aurora๐Ÿ“ Denver Marker Therapeutics, Inc. ยท Tests: MT-601 Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies NCT06699771Phase 13 sites๐Ÿ“ Seoul๐Ÿ“ Seoul๐Ÿ“ Seoul GC Cell Corporation ยท Tests: GCC2005, Cyclophosphamide, Fludarabine Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T NCT06784726Phase 21 site๐Ÿ“ Seattle University of Washington ยท Tests: Odronextamab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Therโ€ฆ Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma NCT07502768Phase 1, Phase 21 site๐Ÿ“ Shanghai Rong Tao ยท Tests: Tislelizumab, Zeprumetostat AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. NCT06137144Phase 1, Phase 238 sites๐Ÿ“ Duarte๐Ÿ“ Miami๐Ÿ“ Atlanta AstraZeneca ยท Tests: AZD3470, Pembrolizumab Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy NCT05757219Phase 21 site๐Ÿ“ Tampa H. Lee Moffitt Cancer Center and Research Institute ยท Tests: Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma NCT05312801Phase 12 sites๐Ÿ“ Cleveland๐Ÿ“ Cleveland Luminary Therapeutics ยท Tests: BAFF CAR-T A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL) NCT04365036Phase 31 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Toripalimab, Pegaspargase, Gemcitabine, Oxaliplatin, Definitive intensity-modulated radiotherapy (IMRT) A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype NCT06522737Phase 344 sites๐Ÿ“ Ghent๐Ÿ“ Leuven๐Ÿ“ Prague SecuraBio ยท Tests: Duvelisib, Gemcitabine, Bendamustine DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers NCT05770037Phase 2, Phase 327 sites๐Ÿ“ Belfast๐Ÿ“ Birmingham๐Ÿ“ Birmingham Cancer Research UK ยท Tests: Alectinib NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma NCT07052305Phase 11 site๐Ÿ“ St Louis Washington University School of Medicine ยท Tests: NT-I7, CAR T-cell therapy Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia NCT06581081NA1 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: Senl_B19 autologous CAR-T (S1904) treatment Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma NCT06649812Phase 2114 sites๐Ÿ“ Tucson๐Ÿ“ Tucson๐Ÿ“ Los Angeles National Cancer Institute (NCI) ยท Tests: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL NCT05370430Phase 16 sites๐Ÿ“ Duarte๐Ÿ“ Stanford๐Ÿ“ Kansas City PeproMene Bio, Inc. ยท Tests: BAFFR-CAR T cells CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia NCT06696846Phase 11 site๐Ÿ“ Hangzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: CD70 CAR-NK Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients NCT04844866Phase 251 sites๐Ÿ“ Graz๐Ÿ“ Innsbruck๐Ÿ“ Linz Miltenyi Biomedicine GmbH ยท Tests: MB-CART2019.1, Standard of Care Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia NCT06793241EARLY Phase 11 site๐Ÿ“ Hangzhou Zhejiang University ยท Tests: CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cells injection A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) NCT05667506Phase 1, Phase 29 sites๐Ÿ“ Hefei๐Ÿ“ Chongqing๐Ÿ“ Guangzhou Juventas Cell Therapy Ltd. ยท Tests: single dose of CNCT19 CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma NCT06209619Phase 11 site๐Ÿ“ Columbus Nathan Denlinger ยท Tests: Biopsy, Biospecimen Collection, Computed Tomography, Golcadomide, Positron Emission Tomography A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) NCT06173518Phase 114 sites๐Ÿ“ Los Angeles๐Ÿ“ Palo Alto๐Ÿ“ Aurora Autolus Limited ยท Tests: AUTO1 A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma NCT06822868Phase 11 site๐Ÿ“ Beijing Kai Hu ยท Tests: CAR T cells Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies NCT06462248Phase 21 site๐Ÿ“ Hong Kong Chi Kong Li ยท Tests: CUCART19 Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma NCT07532525Phase 11 site๐Ÿ“ Ann Arbor University of Michigan Rogel Cancer Center ยท Tests: Biospecimen Collection, Pomalidomide
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy